Mentari Therapeutics (MTRI) News
NASDAQ: MTRIHealth CareBiotechnology: Pharmaceutical PreparationsUSD
14.70-0.545 (-3.57%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
MTRI news summary
We found 3 recent headlines mentioning Mentari Therapeutics (MTRI): 1 in the past week and 3 in the past 30 days, most often from GlobeNewswire, Nasdaq. For price context, MTRI is down 3.57% at $14.70. The most recent story, "InMed Pharmaceuticals Inc. Files Unaudited Financial Statements of Mentari Therapeutics as of September 30, 2026", was published by Nasdaq on Nov 16, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Mentari Therapeutics headlines
- InMed Pharmaceuticals Inc. Files Unaudited Financial Statements of Mentari Therapeutics as of September 30, 2026InMed Pharmaceuticals Inc. (now known as Mentari Therapeutics, Inc.) submitted a Current Report on Form 8-K to file the unaudited condensed consolidated financial statements of Mentari Therapeutics,…Nasdaq
- Mentari Therapeutics to Present at Upcoming Investor ConferencesWALTHAM, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Mentari Therapeutics, Inc. (Nasdaq: MTRI), a clinical-stage biotechnology company developing therapies for migraine prevention, today announced that…GlobeNewswire
- Mentari Therapeutics Announces Closing of Merger with InMed Pharmaceuticals and Previously Announced $490 Million FinancingMentari Therapeutics Announces Closing of Merger with InMed Pharmaceuticals and Previously Announced $490 Million FinancingGlobeNewswire